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Abstract
Integration of signalling downstream of individual receptor tyro-
sine kinases (RTKs) is crucial to fine-tune cellular homeostasis
during development and in pathological conditions, including
breast cancer. However, how signalling integration is regulated and
whether the endocytic fate of single receptors controls such signal-
ling integration remains poorly elucidated. Combining quantitative
phosphoproteomics and targeted assays, we generated a detailed
picture of recycling-dependent fibroblast growth factor (FGF)
signalling in breast cancer cells, with a focus on distinct FGF recep-
tors (FGFRs). We discovered reciprocal priming between FGFRs and
epidermal growth factor (EGF) receptor (EGFR) that is coordinated
at recycling endosomes. FGFR recycling ligands induce EGFR phos-
phorylation on threonine 693. This phosphorylation event alters
both FGFR and EGFR trafficking and primes FGFR-mediated prolifer-
ation but not cell invasion. In turn, FGFR signalling primes EGF-
mediated outputs via EGFR threonine 693 phosphorylation. This
reciprocal priming between distinct families of RTKs from recycling
endosomes exemplifies a novel signalling integration hub where
recycling endosomes orchestrate cellular behaviour. Therefore,
targeting reciprocal priming over individual receptors may improve
personalized therapies in breast and other cancers.
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Introduction
Receptor tyrosine kinases (RTKs), such as fibroblast growth factor
(FGF) and epidermal growth factor (EGF) receptors, respond to
perturbations in the environment by initiating signalling cascades in
proximity to the plasma membrane upon binding of their growth
factors (Wintheiser & Silberstein, 2020). Ligand-induced proximal or
early signalling is then amplified through cascades—such as the
mitogen-activated protein kinase (ERK, p38), phosphoinositide 3-
kinase (PI3K) and phospholipase Cγ (PLCγ) pathways—specifies cell
fate and controls cellular homeostasis during development and in
pathological conditions (Lemmon & Schlessinger, 2010). Indeed,
deregulated early signalling and signalling rewiring are responsible
for unwanted long-term outputs, such as increased proliferation and
motility, in human diseases, including cancer (Du & Lovly, 2018).
This is the main reason why signalling molecules are the target of
most of the known cancer therapies (Yaffe, 2019). However, each
RTK is not an isolated entity on the plasma membrane, but func-
tions within complex networks with other RTKs to fine-tune cancer
cell intracellular signalling and long-term fate decisions. Indeed,
targeting single molecules is often not enough to switch off
unwanted cancer cell responses, as highlighted for instance in breast
cancer (Harbeck et al, 2019). Recent advances in mass spectrometry
(MS)-based phosphoproteomics allows us to simultaneously analyse
thousands of signalling molecules and their post-translational modi-
fications (PTMs) (Huang, 2012; Doll et al, 2019; Lundby et al, 2019;
Bludau & Aebersold, 2020). However, how different RTK families
integrate their downstream signalling has not been comprehensively
analysed yet. A better understanding of the molecular mechanisms
used by RTKs to coordinate each other’s signalling architecture will
help to identify how to interfere with the right target at the right
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time to re-direct deregulated cancer cell behaviours. This idea would
also support the current therapeutic concept in breast cancer aiming
at personalized combination of therapies at early stage of treatment
prior to the acquisition of resistance or to delay it (Harbeck et al,
2019).
Multiple mechanisms contribute to shape signalling architec-
ture, including the nature and affinity of the receptor ligand (Zin-
kle & Mohammadi, 2019), receptor co-activation (Tan et al, 2017),
feedback mechanisms (Nguyen & Kholodenko, 2016) and the
spatio-temporal distribution of signalling transducers (Bergeron
et al, 2016). Ligand-dependent endocytic trafficking (hereafter
trafficking) of RTKs from and to the plasma membrane regulates
early signalling and downstream responses (Goh & Sorkin, 2013;
Schmid, 2017; Budick-Harmelin & Miaczynska, 2018). For instance,
we have shown that fibroblast growth factor 10 (FGF10) and trans-
forming growth factor α (TGFα) initiate specific early signalling
events that regulate FGFR2b and EGFR recycling to the plasma
membrane, respectively, resulting in enhanced cell motility (Fran-
cavilla et al, 2013; Francavilla et al, 2016). It is, however,
unknown whether ligand-induced recycling plays a role in the
signalling interplay between RTKs to coordinate long-term
responses. This concept is supported by alterations in the ability of
cancer cells to migrate and proliferate due to derailed RTK traf-
ficking (Mellman & Yarden, 2013; Lanzetti & Di Fiore, 2017) and
by EGFR/integrin recycling-dependent regulation of cancer cell
migration (Caswell & Norman, 2008).
Here, to study how ligand-induced trafficking—and more
specifically recycling to the plasma membrane—affected signalling
coordination downstream from FGFRs in breast cancer cells we
combined quantitative phosphoproteomics and targeted assays.
FGFRs are a large family of RTKs composed of alternatively
spliced isoforms of four genes (Fgfr1b-c, Fgfr2b-c, Fgfr3b-c, Fgfr4),
where the “b” and “c” isoforms are expressed mainly on epithe-
lial and mesenchymal cells, respectively (Ornitz & Itoh, 2015).
More than 22 FGF ligands exist (Ornitz & Itoh, 2015), making
FGF/FGFR an ideal system to study trafficking-dependent signal-
ling integration. FGFRs play an important yet understudied role in
breast cancer and are deregulated in a significant percentage of
the oestrogen/progesterone receptor (ER/PR) and triple-negative
breast cancer (TNBC) subtypes of breast cancer (Babina & Turner,
2017; Navid et al, 2020). Furthermore, FGFs are essential for pro-
ficient breast cancer organoid growth (Sachs et al, 2018), but
their role in vivo is less clear (Clayton & Grose, 2018; Watson &
Francavilla, 2018; Navid et al, 2020). Although breast cancer is
known to have deregulated RTK signalling and trafficking (Butti
et al, 2018), the functional consequences of recycling in breast
cancer cells are yet to be determined. It is also unclear how
ligand, receptor, and protein adaptors integrate trafficking and
signalling to fine-tune breast cancer cellular responses. Therefore,
to dissect recycling-dependent integration of signalling outputs
from multiple angles, we developed three quantitative trafficking
phosphoproteomics approaches (TPAs), which focused on recy-
cling FGFs-, recycling FGFRs- and recycling adaptor-dependent
signalling (Fig 1A). To our knowledge, previous global studies of
the trafficking-signalling enigma focused on a single question,
either uncovering general trafficking regulators by genetic screen-
ing or multiparametric imaging analysis (Collinet et al, 2010;
Liberali et al, 2014; Gut et al, 2018) or revealing the partners of
trafficking effectors by proximity labelling methods (Gillingham
et al, 2019). Here, we constructed for the first time a snapshot of
FGFR recycling-dependent signalling in breast cancer cells and
provided a comprehensive resource for the trafficking, signalling
and cancer communities. We unexpectedly identified a novel
signalling interplay between FGFR and EGFR from the recycling
endosomes. Specifically, FGFR recycling ligands induce phospho-
rylation on EGFR at the non-catalytic threonine T693 (T669 in the
UniProt sequence P00533) that reciprocally affects both FGFR and
EGFR signalling outputs in breast cancer cells. We have therefore
elucidated reciprocal priming between FGFR and EGFR which is
based on an early phosphorylation-dependent signal and which
coordinates trafficking-dependent signalling outputs.
Results
TPAs unmask FGFR-dependent EGFR_T693 phosphorylation
To investigate recycling-dependent signalling in breast cancer cells,
we compared the FGFR2b recycling stimulus FGF10 to FGF7, which
induces FGFR2b degradation (Francavilla et al, 2013) (Fig 1B and C,
Appendix Fig S1A and B), and analysed changes in the global signal-
ling of a panel of five FGFR2b-expressing breast cancer cell lines
(Francavilla et al, 2013) (Appendix Fig S1C). The breast cancer cell
lines were treated with FGF7 or FGF10 for 1 or 8 min., and such
early signalling was analysed using phosphoproteomics, hereafter
referred to as trafficking phosphoproteomics approach 1 (TPA1)
(Fig 1A). TPA1 showed a high degree of reproducibility in four inde-
pendent experiments with the identification of phosphorylated
peptides in the high intensity range and the quantification of 4559
proteins and 9494 phosphorylated sites in total, consistent with
previous publications (Lundby et al, 2019) (Appendix Fig S1C–I,
Datasets EV1 and EV2). Hierarchical clustering of the differentially
regulated phosphorylated sites showed clustering of breast cancer
cell lines based on their known molecular subtypes (Neve et al,
2006), within which we identified clusters based on FGFR2b-specific
early signalling (Appendix Fig S2A). We focused on the 5 cell line-
specific FGFR2b signalling clusters identified across the breast
cancer cell lines (32.5% of the phosphoproteome) and found an
enrichment for proteins involved in signalling pathways, adhesion
and establishment of localization (endocytosis and transport)
common to all cell lines (Appendix Fig S2B). Within these 5 clus-
ters, 78 kinases were identified as being phosphorylated
(Appendix Fig S2C) and 12 of them were associated with the Gene
Ontology (GO) terms establishment of localization and/or adhesion
—including EGFR—consistent with enrichment of all proteins
(Appendix Fig S2B and C). To study the differential phosphopro-
teomes downstream from FGF7 and FGF10, we focused on T47D
and BT20. Each cell line represents a distinct breast cancer molecu-
lar subtype (Neve et al, 2006), mirrored in FGFR2b-specific clusters
(Appendix Fig S2A). Furthermore, these cell lines express different
levels of Fgfr2b (Appendix Fig S2D) and respond to FGF7/10 stimu-
lation, as shown by increasing phosphorylation of ERK and cell
proliferation (Watson & Francavilla, 2018) (Fig 1D, Appendix Fig
S2E–G). Interestingly, hierarchical clustering showed that each FGF
separated the phosphoproteome to a greater extent than the dura-
tion of stimulation (Fig 1E and F, Appendix Fig S2H and I),
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confirming the uniqueness of ligand responses (Francavilla et al,
2013). Analysis of the FGF7- and FGF10-specific clusters showed
enrichment of the GO term protein localization unique to FGF10
stimulation in both T47D and BT20 (Fig 1E and F, Appendix Fig
S2H and I). In support of the idea that the FGF10 phosphoproteome
regulates protein localization in breast cancer cells, we found that
the FGF10 phosphorylated proteins were enriched in all cellular
compartments including endosomes and that 63% of them were
ascribed to human diseases, including breast cancer (Pletscher-
Frankild et al, 2015; Fig 1G). Furthermore, the FGF10-regulated
phosphoproteome in T47D and BT20 contained TTP and RCP (Fig 1
G), known to regulate FGFR2b and EGFR recycling, respectively
(Francavilla et al, 2013; Francavilla et al, 2016). Confocal micro-
scopy confirmed that FGF10-induced FGFR2b recycling required
TTP (Francavilla et al, 2013), but also RCP (Fig 1H and I,
Appendix Fig S2J). Altogether, these data highlight a role for TTP
and RCP in FGFR2b trafficking and early signalling specifically
induced by the recycling ligand FGF10 in breast cancer cells.
Next, we studied how widely recycling affects signalling in
breast cancer cells by assessing the contribution of three recycling
FGFRs and of the recycling adaptors TTP and RCP to changes in
the phosphoproteome, hereafter referred to as TPA2 and TPA3,
respectively (Fig 1A, Datasets EV3–EV5). TPA2 compares the
signalling downstream of recycling FGFRs in a defined genetic
background. We overexpressed FGFR1c, 2b, or 4 in BT549 cells,
which lack these FGFRs, and stimulated cells with Enkamin-E,
FGF10, or FGF1 for 8 and 40 min., respectively (Fig 2A). It is
known that each of these ligands induced recycling of the paired
receptor (Haugsten et al, 2005; Francavilla et al, 2013; Francavilla
et al, 2016) and we showed also ligand-dependent sustained
signalling activation (Appendix Fig S3A and B). Hierarchical clus-
tering of the 6402 phosphorylated sites from this high-quality
dataset (Appendix Fig S3C–H) identified a cluster related to early
signalling (8 min) and one associated with late endosomal signal-
ling (40 min.) common to all the considered FGFR-ligand pairs
(Fig 2B). Refined analysis of this recycling receptor cluster revealed
a signalling network of 866 proteins of which 38 were known
trafficking proteins and 24, among which EGFR, TTP and RCP,
were also identified by TPA1 (Figs 1 and 2C, and Appendix Figs
S1–S3I). TPA3 analysed the FGF10-dependent phosphoproteome
of T47D in the presence or absence of the recycling adaptors TTP
or RCP (Fig 2D, Appendix Fig S3J). We identified 9569 phospho-
rylated sites and verified the high level of correlation between
replicates of TPA3 (Appendix Fig Sl-O). Hierarchical clustering
identified TTP- and RCP-specific clusters and a common recycling
adaptor cluster (Fig 2E). The analysis of 113 proteins associated
with the GO term establishment of localization in the latter clus-
ter revealed 22 proteins already identified by TPA1, of which 6
were kinases, including EGFR (Figs 1 and 2F, and Appendix Figs
S1, S2 and S3P). To identify key regulators of signalling down-
stream from FGFR recycling in breast cancer cells based on the
multi-angle TPAs, we focused on phosphorylated proteins belong-
ing to the GO term establishment of localization and prioritized
the 22 phosphorylated proteins in common to the three TPAs
(Fig 2G). This group of proteins included scaffolding proteins
and the three protein kinases AKT, PAK1 and, strikingly, EGFR
(Fig 2G). Assessment of EGFR-phosphorylated sites that were dif-
ferentially regulated within each TPA highlighted that the phos-
phorylation of the non-catalytic threonine 693 (EGFR_T693) was
uniquely associated with a recycling signature (40 min. upon
stimulation) (Fig 2G). Therefore, the three quantitative TPAs
developed to study FGFR recycling-dependent signalling integra-
tion in breast cancer cells (Fig 1A) unveiled a FGFR recycling-
associated EGFR_T693 phosphorylation (Figs 1G, 2C, F, G and
Datasets EV1–EV5). This finding suggests a hitherto unknown
signalling interplay between FGFRs and EGFR in breast cancer
cells. As EGFR_T693 phosphorylation is critical for EGF-induced
EGFR internalization (Heisermann et al, 1990) and is induced by
the EGFR recycling stimulus TGFα in a sustained manner (Fran-
cavilla et al, 2016), we hypothesized that EGFR_T693 phosphory-
lation may contribute towards FGFR outputs that depend on
FGFR recycling.
◀ Figure 1. Trafficking phosphoproteomics reveals FGFR2b recycling-dependent outputs.
A Overview of the trafficking phosphoproteomic approaches (TPAs).
B Internalization (cytoplasm) and recycling (plasma membrane) of FGF7- and FGF10-stimulated endogenous FGFR2 (green) for 0, 15, 40, and 120 min. in T47D. TRITC-Tf
is a marker of recycling (red). Nuclei are stained in blue. *, cells with receptor recycled to the plasma membrane. Scale bar, 5 μm.
C Red and green pixels overlap fraction representing the co-localization of FGFR2b with the recycling endosomes marker Tf (above) and the proportion of green over
total pixels representing FGFR2b in the cytoplasm (below) upon stimulation with FGF7 (dark green) or FGF10 (burgundy) for 15, 40, or 120 min. Values represent the
median  SD of at least 3 independent experiments. Representative pictures are shown in B (cytoplasm). *P < 0.005 (Student’s t-test).
D Confluence over time of BT20, T47D, and BT549 transfected with HA-FGFR2b stimulated with FGF7 (dark green) or FGF10 (burgundy). Data represent the mean  SD
of N = 3 compared with FGF10. P =< 0.05*, < 0.01**, < 0.001*** (Student’s t-test).
E Hierarchical clustering of the phosphorylated sites differentially quantified T47D stimulated with FGF7 (green) or FGF10 (burgundy). Specific clusters are highlighted
with black lines. The intensity of phosphorylated sites is presented on the logarithmic scale with intensity below and above the mean colour-coded in blue and red,
respectively.
F Enriched terms in the selected clusters of E, cluster FGF10 (burgundy, top), cluster FGF7 (green, bottom).
G Network of phosphorylated proteins belonging to “protein localization” in FGF10 clusters, based on STRING, visualized in Cytoscape, and colour-coded based on
cell components. The squared shape represents phosphorylated proteins found in the database DISEASES. The recycling adaptors TTP and RCP are highlighted
in grey.
H Internalization (cytoplasm) and recycling (plasma membrane) of FGF10-stimulated HA-FGFR2b (green) transfected in BT549 stimulated for 0, 40 and 120 min. Cells
were depleted or not of TTP or RCP by a pool of siRNAs. TRITC-Tf is a marker of recycling (red). Nuclei are stained in blue. *, cells with receptor recycled to the plasma
membrane. Scale bar, 5 μm.
I The presence (total), internalization (internalized) and recycling (cell surface) of transfected HA-FGFR2b in BT549 upon stimulation were quantified as in (Francavilla
et al, 2016) and in the section “Quantification of the Recycling assay”. Values represent the median  SD of N = 3. Representative pictures upon FGF10 stimulation
are shown in H.
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EGFR_T693 phosphorylation is FGFR2b ligand-, recycling- and
activation-dependent
To verify the potential interplay between FGFR and EGFR, we
first validated EGFR_T693 phosphorylation in T47D, BT20, HA-
FGFR2b-BT549 and a breast cancer organoid grown from a TNBC
patient-derived xenograft (PDX) tumour (Eyre et al, 2016). FGF10,
but not FGF7, induced EGFR phosphorylation on T693, whilst
leaving the catalytic residue tyrosine 1068 (Y1068) unaltered at
40-min. stimulation (Maennling et al, 2019). By contrast, the
EGFR ligands EGF and TGFα induced the phosphorylation of both
T693 and Y1068, as shown previously (Ceresa & Peterson, 2014)
(Fig 2H and I). Therefore, sole phosphorylation of EGFR at T693
is FGF10/FGFR2b-specific.
To confirm that FGF10-induced FGFR2b recycling was involved
in EGFR_T693 phosphorylation, we depleted TTP or RCP and stimu-
lated T47D and BT20 with FGF10 for 40 min. This resulted in
decreased EGFR_T693 phosphorylation and ERK activation upon
depletion of either recycling adaptor (Appendix Fig S4A and B).
Overexpressing siRNA-resistant TTP or RCP restored both
EGFR_T693 phosphorylation and ERK phosphorylation following
FGF10 stimulation (Fig 2J). Furthermore, we observed a peak in
EGFR_T693 phosphorylation at 40 min. post-stimulation with
FGF10 when FGFR2b was present in recycling endosomes (Fig 1B–I,
Appendix Fig S4C). Finally, FGF10-mediated phosphorylation of
EGFR_T693 decreased when FGFR2b trafficking was inhibited by
dominant-negative Rab11 (preventing recycling) or dominant-
negative dynamin (preventing internalization) with no discernible
alterations in ERK activation (Appendix Fig S4D-G). As TGFα or
EGF-induced EGFR_T693 phosphorylation occurs regardless of
length of stimulation, or trafficking inhibition (Fig 2J, Appendix Fig
S4), we concluded that EGFR_T693 phosphorylation is independent
of EGFR recycling, but FGFR2b-induced phosphorylation of EGFR
on T693 requires recycling upon FGF10 stimulation.
We next verified whether the kinase activity of FGFR was
required for EGFR_T693 phosphorylation. Enkamin-E, FGF10 and
FGF1 induced EGFR_T693 phosphorylation in cells expressing
their cognate receptors, but this was suppressed by the FGFR inhi-
bitor PD173074 (Pardo et al, 2009) (Fig 3A and B). Similarly,
FGF10-dependent EGFR_T693 phosphorylation decreased in cells
transfected with the catalytically inactive HA-FGFR2b_Y656F/Y657F
(Francavilla et al, 2013) (Fig 3C). Furthermore, FGF10, but not
TGFα, required FGFR activation to induce EGFR_T693 phosphoryla-
tion and ERK activation in breast cancer cells expressing endoge-
nous FGFR2b (Fig 3D). Conversely, TGFα-, but not FGF10-induced
EGFR_T693 phosphorylation was blocked by the EGFR inhibitor
AG1478 (Han et al, 1996) (Fig 3D). These data suggest that EGFR_T693
phosphorylation downstream from FGFR ligands depends on FGFR but
not EGFR activation. As a conserved proline follows T693 on EGFR and
TPA2-3 uncovered an ERK-kinase-substrate (or proline in +1) motif
encompassing the phosphorylated EGFR (Figs 2 C–F and 3E), we
treated T47D and BT20 with MEK inhibitors, U0126 and MEK162
(Cheng & Tian, 2017), or the p38 kinase inhibitor BMS582949 (Emami
et al, 2015) (Fig 3A). Both MEK inhibitors blocked ERK phosphoryla-
tion in cells stimulated with FGF10 and TGFα, and EGFR_T693 phos-
phorylation was simultaneously decreased upon FGF10 treatment, and
to lesser extent upon TGFα, whereas p38 inhibition had no effect
(Fig 3F–G). Therefore, EGFR_T693 phosphorylation depended on MEK-
ERK, but not p38, signalling upon FGF10 stimulation.
In conclusion, FGF ligands which induce the recycling of their
paired FGFR receptor increase EGFR_T693 phosphorylation via
FGFR and ERK signalling, independent of EGFR or p38 activity.
FGF10 primes EGFR responses
To explore the consequences of the FGFR and EGFR interplay, we
first tested the effect of FGF10 on EGFR functions. FGF10 stimula-
tion did not alter the levels of EGFR, which decrease over time upon
EGF—and to a lesser extent TGFα—stimulation (Francavilla et al,
2016) (Fig 4A). However, if T47D cells were pre-treated for 40 min
with FGF10, followed by stimulation with EGF for different time
points, we observed an increase in EGFR abundance and ERK acti-
vation relative to cells not pre-treated with FGF10 for 120 min (Fig 4
B). FGF10 pre-treatment did not have the same effect on EGFR stabi-
lization from the recycling stimulus TGFα at 120 min and a less
pronounced effect on ERK phosphorylation at any time point. These
data suggest that FGF10 pre-treatment alters EGF signalling to
increase stability of EGFR at 120 min resulting in higher levels of
◀ Figure 2. TPA2-3 unveil FGF10-dependent EGFR_T693 phosphorylation.
A Experimental design of TPA2.
B Hierarchical clustering of the phosphorylated sites differentially quantified in BT549 transfected with HA-FGFR1c, 2b or 4 and stimulated for 8 or 40 min. with
Enkamin-E, FGF10 or FGF1, respectively. Early signalling and recycling receptor clusters are highlighted in light and medium blue, respectively. The intensity of
phosphorylated sites is presented on the logarithmic scale with intensity below and above the mean colour-coded in blue and red, respectively.
C STRING-based and Cytoscape-visualized network of the phosphorylated proteins belonging to “endocytosis” (clusters medium blue in b). The diamond shape
represents phosphorylated proteins found in TPA1. Kinases are highlighted in burgundy. The border is colour-coded based on the substrate motifs.
D Experimental design of TPA3.
E Hierarchical clustering of the phosphorylated sites differentially quantified in T47D stimulated with FGF10 and depleted or not of TTP or RCP. The clusters for TTP
adaptors, RCP adaptors or recycling adaptors are highlighted in orange, brown and light green, respectively. The intensity of phosphorylated sites is presented on
the logarithmic scale with intensity below and above the mean colour-coded in blue and red, respectively.
F STRING-based and Cytoscape-visualized network of phosphorylated proteins belonging to the recycling adaptor cluster (light green in E) and found in TPA1. Kinases
are highlighted in burgundy. The border is colour-coded based on the substrate motifs.
G Venn diagram showing the phosphorylated proteins belonging to “establishment of localization” identified in TPA1-3 (left). STRING-based and Cytoscape-visualized
network of the 22 proteins identified by the 3 TPAs (centre). Phosphorylated sites quantified on EGFR (right). T693 is highlighted in yellow.
H–J Lysates from (H) T47D, BT20 and HA-FGFR2b-transfected BT549 stimulated or not with FGF7, FGF10, EGF and TGFα for 40 min; (I) breast cancer organoid cultured
from the PDX tumour BB6RC37 and grown for the last 24 h as indicated; (J) control or 40 min. FGF10- or TGFα-stimulated T47D left untreated or depleted of TTP,
followed or not by transfection with siRNA-resistant Flag-TTP (Flag-TTP*) or depleted of RCP followed or not by transfection with siRNA-resistant RCP-GFP (RCP-
GFP*) were immunoblotted with the indicated antibodies. **, non-specific band (J).
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ERK activation. FGFR2 levels remained high with all treatment
conditions; however 40 min., FGF10 pre-treatment did alter the
dynamics of FGFR2b downstream of both EGF and TGFα stimula-
tion. The effect of FGF10 pre-treatment on EGFR dynamics in EGF-
stimulated cells depended on both FGFR and ERK activities (Fig 4C
and D). When EGFR was stabilized with AG1468 (Gan et al, 2007),
the stability of the EGFR following pre-treatment was in line with
FGF10 40-min stimulation, whereas ERK activation decreased (Fig 4
E). Therefore, FGF10 pre-treatment increases the total levels of
EGFR after EGF stimulation, and this resulted in sustained ERK
phosphorylation, an effect dependent on the activation of the FGFR-
ERK signalling axis. Correspondingly, FGF10 pre-treatment followed
by EGF stimulation for 4h induced the highest expression of ERK
late target genes (Uhlitz et al, 2017) (Fig 4F), which may suggest
enhanced cell cycle progression (Sharrocks, 2006). This was con-
firmed by increased EdU incorporation in T47D and BT20 stimulated
with EGF upon pre-treatment with FGF10 (Fig 4G, Appendix Fig
S5A). The use of specific inhibitors indicated that FGF10 signifi-
cantly increased EGF-dependent cell cycle progression in an FGFR-,
ERK-, and EGFR-dependent manner (Fig 4G and H and
Appendix Fig S5).
In conclusion, FGF10 pre-treatment stabilizes EGF-stimulated
EGFR via FGFR-ERK signalling. Elevated ERK phosphorylation,











































































































































































































































Compound    Target
PD173074     FGFR
AG1478         EGFR
U0126           MEK
MEK162        MEK
BMS582949  p38 
Figure 3. FGF10-dependent EGFR_T693 phosphorylation requires FGFR and ERK.
A List of compounds and their targets.
B–D Lysates from BT549 transfected with HA-FGFR1c, 2b, or 4 and stimulated for 8 or 40 min with Enkamin-E, FGF10 or FGF1, respectively, followed by treatment with
either DMSO or the FGFR inhibitor PD173074 (B); BT549 transfected with HA-FGFR2b or HA-FGFR2b_Y656F/Y657F and stimulated with FGF10 for 40 min. (C); T47D
treated with DMSO, PD173074 or the EGFR inhibitor AG1478 and stimulated or not with either FGF10 or TGFα for 0, 8 and 40 min. (D) were immunoblotted with
the indicated antibodies.
E Protein sequences surrounding T693 (based on UniProt P00533) of members of the ErbB family were aligned using CLUSTAL O (version 1.2.4). The red box indicates
that the amino acid T is followed by a conserved proline. Asterisks below the sequences indicate identical amino acid residues; double dots indicate conserved
amino acid residues; single dots indicate semi-conserved substitutions.
F, G Lysates from T47D or BT20 treated with DMSO, PD173074, AG1478 or the MEK inhibitors U0126 and MEK162 and stimulated or not with either FGF10 or TGFα (F);
T47D or BT20 treated with DMSO, or the p38 inhibitor BMS582949 and stimulated or not with either FGF10 or TGFα (G) were immunoblotted with the indicated
antibodies.
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cycle progression suggest that FGF10 pre-treatment primes EGF
responses and confirms a functional interplay between FGFR and
EGFR signalling.
FGF10-dependent EGFR_T693 phosphorylation in the recycling
endosome reciprocate priming of FGFR2b outputs
The FGFR/EGFR interplay was also verified by uncovering the co-
localization of FGFR2b with EGFR in recycling endosomes upon 40-
min. stimulation with FGF10, but not with TGFα (Fig 5A and B,
Appendix Fig S6A and B). Intriguingly, EGFR was phosphorylated
on T693 in recycling endosomes at 40, but not at 20 min, in
response to FGF10 (Fig 5C and D, Appendix Fig S6C). We therefore
hypothesized that the recycling endosomes may form the interface
for FGFR and EGFR signal integration, perhaps involving physical
interaction of the receptors, and that EGFR_T693 phosphorylation
could affect FGFR2b trafficking. We assessed FGFR2b/EGFR co-
localization and co-immunoprecipitation in T47D cells depleted of
endogenous EGFR and transfected with either EGFR wild-type (wt)
or the T693A mutant (T693A)—which cannot be phosphorylated at
residue T693—upon a time-course stimulation with FGF10 (Fig 5,
Appendix Fig S6, Appendix Fig S7A and B). Under non-stimulated
conditions, FGFR2b co-localized at the plasma membrane and co-
immunoprecipitated with both wt and T693A EGFR (Fig 5E–G,
Appendix Fig S6D–F). At 20-min. stimulation with FGF10, FGFR2b
was detected in the recycling endosomes in both wt- and T693A-
expressing cells, but it failed to interact or localize with either EGFR
as both were still located at the plasma membrane (Fig 5E–F, Figs
EV1 and EV2, Appendix Fig S6G). Therefore, FGFR2b traffics to the
recycling endosomes before interacting with EGFR. We also
observed that FGFR2b localization to the recycling endosomes in
FGF10 stimulated wt-expressing cells for 40 min. was lost in the
presence of T693A. At this time point, FGFR2b co-
immunoprecipitated with both wt and T693A (Fig 5G), but co-
localized with wt in recycling endosomes and with T693A at the
plasma membrane. These data imply that FGFR2b trafficking is
altered in cells expressing T693A EGFR. Interestingly, RCP failed to
interact with FGFR2b in T693A-expressing cells stimulated for
40 min. with FGF10 (Fig 5G, Appendix Fig S6F, suggesting that RCP
and EGFR interact with FGFR2b in recycling endosomes in a T693
phosphorylation-dependent manner. Finally, at 60-min stimulation
with FGF10, we detected FGFR2b and EGFR at the plasma
membrane in both wt- and T693A-expressing cells (Fig 5E–G,
Appendix Fig S6F–G). TGFα stimulation of T693A-expressing cells
confirmed that T693 phosphorylation regulates EGFR internalization
(Heisermann et al, 1990), as the T693A receptor was unable to traf-
fic from the plasma membrane under any of the tested conditions
(Fig 5E and F). Using GFP-Rab11-APEX2, which did not affect
FGFR2b trafficking (Appendix Fig S6H), we assessed at which time
point the majority of EGFR phosphorylated on T693 was detected in
proximity to the recycling endosomes following FGF10 stimulation.
In agreement with the confocal imaging, we found that EGFR phos-
phorylation on T693 accumulated at the recycling endosomes
between 20- and 40-min stimulation, when FGFR2b was detected in
recycling endosomes together with RCP (Appendix Fig S6G–I,
Fig 5). Altogether, these data suggest that EGFR_T693 phosphoryla-
tion dynamically regulates FGFR2b trafficking after the formation of
an FGFR2b/EGFR/RCP complex in the recycling endosomes. Indeed,
in T693A-expressing and in cells treated with FGFR and ERK inhibi-
tors, but not EGFR or p38 inhibitors, there is less intracellular
FGFR2b and increased receptor at the cell surface at 40-min. stimu-
lation (Fig 5H, Appendix Fig S6J and K). Therefore, FGF10-
dependent EGFR_T693 phosphorylation via FGFR and ERK activa-
tion (Fig 3) plays a role in the spatio-temporal regulation of FGFR2b
trafficking.
To test the cellular impact of FGFR/EGFR signalling integration
by quantifying whether EGFR_T693 phosphorylation affects FGF10
signalling downstream from FGFR2b, we compared the phosphopro-
teome of T47D expressing either wt or T693A EGFR upon stimula-
tion with FGF10 for 40 or 60 min (Fig 6A, Dataset EV6). We
confirmed the absence of T693 phosphorylation of T693A EGFR,
whilst other EGFR residues and ERK were phosphorylated in both
wt- and T693A-expressing cells (Appendix Fig S7A and B). The
reproducibility of this dataset was consistent with the previous ones
(Appendix Figs S1–S3, S7C–G, Datasets EV1–EV6). Hierarchical
clustering of the 6485 identified phosphorylated sites revealed 4
clusters. Three clusters grouped sites whose phosphorylation
increased in T693A- compared with wt-expressing cells. These clus-
ters (plasma membrane response, acquired response, and late
response) were enriched for general cellular processes (Fig 6B and
C). The fourth cluster (T693 phosphorylation-dependent response)
represented phosphorylated sites dependent on EGFR_T693 phos-
phorylation downstream from FGF10 signalling (Fig 6B and C). Of
the 102 phosphorylated sites identified on the 53 kinases within all
the four clusters, 10 were known regulatory sites (Fig 6D, Datasets
EV6 and EV7). More specifically, FGF10-stimulated T693A-
expressing cells showed decreased phosphorylation of proteins
belonging to the GO term cell cycle, including the activating T161
site on the cell cycle regulator cyclin-dependent kinase 1 (CDK1)
(Coulonval et al, 2011) (Fig 6D, Appendix Fig S7H, Dataset EV7).
We confirmed that FGF10 induced CDK1_T161 phosphorylation in
wt-, but not T693A-expressing T47D and BT20 cells (Fig 6E–F).
Furthermore, FGF10-mediated cell cycle progression decreased in
T693A-expressing cells, an effect due to impaired EGFR_T693 phos-
phorylation, as the total level of EGFR wt or T693A did not alter
over time (Fig 7A and B, Appendix Fig S7I). Therefore, FGF10-
◀ Figure 4. FGF10 primes EGFR responses.
A–E Lysates from T47D stimulated or not with FGF10, EGF or TGFα for different time periods (A); pre-treated or not with FGF10 for 40 min. and either stimulated or
not with FGF10, EGF or TGFα for different time periods (B) or treated with PD173074 (C), MEK162 (D), AG1478 (E) before stimulation were immunoblotted with the
indicated antibodies.
F Heatmap of the mRNA relative expression of the indicated ERK targets compared with control and quantified by qPCR. N = 3. The minimum and maximum fold-
induction is colour-coded in white and burgundy, respectively.
G, H Percentage of EdU incorporation in T47D pre-treated or not with FGF10 for 40 min. and stimulated or not with FGF10 or EGF (G) or incubated with MEK162,
PD173074 or AG1478 before pre-treatment (H). N = 6. P =< 0.05*, < 0.01**, < 0.001*** (one-way ANOVA with Tukey test).
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mediated FGFR2b recycling, CDK1 phosphorylation, and the level of
cell cycle progression all depend on EGFR_T693 phosphorylation.
Finally, FGF10-dependent EGFR_T693 phosphorylation plays a
crucial role in FGF10 priming of EGFR responses, as shown by
decreased EdU incorporation in T693A-expressing T47D and BT20
cells stimulated with FGF10 for 40 min prior to TGFα treatment
(Fig 7C and D). We have previously shown that FGF10-mediated
FGFR2b recycling regulates cell migration (Francavilla et al, 2013)
and RTK recycling is known to increase cell motility (Crupi et al,
2020). As FGFR2b recycling was impaired in T693A-expressing cells
(Fig 5), we then investigated whether EGFR_T693 phosphorylation
was required for cell invasion. Surprisingly, FGF10 stimulation
increased cell invasion in both wt- and T693A-expressing cells
(Fig 7E and F), implying that EGFR_T693 phosphorylation is not
important for FGF10-induced cell invasion. In conclusion, our data
showed that recycling endosomes facilitate EGFR_T693 phosphory-
lation induced by FGF10 and that T693 phosphorylation is required
for the full response to FGF10 and for FGF10 to prime EGF
responses (Fig 7G, Fig EV3).
Overall, the “reciprocal priming” between FGFR and EGFR is a
novel mechanism to coordinate the trafficking and the signalling
outputs of these two RTKs in breast cancer cells.
Discussion
This study shows that FGFR activation primes EGF-mediated
responses in breast cancer cells whilst inducing EGFR_T693 phos-
phorylation from the recycling endosomes. Such phosphorylation
events in turn modify the FGFR responses. This reciprocal priming
between FGFR and EGFR from the recycling endosomes alters the
dynamics of recycling and enhances cell cycle progression, but not
cell invasion, downstream from both RTKs. It represents the first
early, selective and multi-functional mechanism of RTK signalling
integration which drives long-term outputs. In contrast to the
known RTK cross-talk, where the inhibition of a dominant RTK
may result in the compensatory recruitment of signalling molecules
to a second RTK (Cao, 2016), reciprocal priming does not occur
sequentially, rather simultaneously during the entry route of each
RTK into the cytoplasm. This is an efficient way to rapidly change
cell behaviour in response to the presence of a combination of
ligands in the cell environment. Based on our comprehensive
resource which integrates four quantitative phosphoproteomics
datasets, we suggest that several recycling and signalling factors
identified in this study may play a role in ensuring the co-
localization of RTKs in the same cellular compartment. TPAs can
be also explored by the community to pinpoint the molecular deter-
minants of RTK recycling-dependent signalling in breast cancer
cells. We therefore envision that reciprocal priming discovered in
this study is unlikely to be restricted to FGFR and EGFR, opening
up an exciting and novel avenue of RTK biology to be inves-
tigated. For instance, it remains to be determined whether
FGFs induce the phosphorylation of threonine residues via ERK
activity also on other RTKs. The discovery of a similarly phos-
phorylated peptide on c-Met depending on FGFRs recycling (Fig 2
C, Dataset EV4) and on other members of the EGFR family (Fig 3
E) suggests the presence of a network among RTKs in the recy-
cling endosomes.
Besides regulating EGFR trafficking (Heisermann et al, 1990),
T693 phosphorylation is a highly conserved residue (see response to
referees in Review Process File available online) and involved in the
response to stress or to the anti-tumour agent cisplatin via p38 acti-
vation (Winograd-Katz & Levitzki, 2006; Zwang & Yarden, 2006).
Here, we show that FGFR ligands can induce EGFR_T693 phospho-
rylation and that T693 phosphorylation is required for the full acti-
vation of FGF10 responses and for FGF10 priming of EGFR outputs.
This increases the repertoire of stimuli, including tumour necrosis
factor-α (TNF-α) (Singhirunnusorn et al, 2007) or the Eph family
◀ Figure 5. EGFR_T693 phosphorylation regulates FGFR2b recycling.
A Co-localization of FGFR2 (red), EGFR (green) and the recycling marker Tf (blue) in T47D stimulated or not with FGF10 or TGFα for 40 min. Scale bar, 5 μm.
B Red and green pixels overlap fraction (above, left) representing the co-localization of FGFR2 with EGFR; red and far-red pixels overlap fraction (above, right)
representing the co-localization of FGFR2 with the recycling marker Tf; far-red and green pixels overlap fraction (below, left) representing the co-localization of EGFR
with the recycling marker Tf; green, red and far-red pixels overlap fraction (below, right) representing the co-localization of FGFR2, EGFR, and the recycling marker Tf
in T47D stimulated for 40 min. Values represent the median  SD of at least 3 independent experiments. Representative pictures are shown in A and Appendix Fig
S6A. *, P‐value<0.005 (Student’s t-test).
C Co-localization of EGFR (green), T693 phosphorylated EGFR (blue) and the recycling marker Tf (red) in T47D stimulated or not with FGF10 or TGFα for 40 min. Scale
bar, 5 μm.
D Red and green pixels overlap fraction (above) representing the co-localization of EGFR with the recycling marker Tf; green, red and far-red pixels overlap fraction
(below) representing the co-localization of EGFR, phosphorylated EGFR and the recycling marker Tf in T47D stimulated for 40 min. Values represent the median  SD
of at least 3 independent experiments. Representative pictures are shown in C and Appendix Fig S6C. *P < 0.005 (Student’s t-test).
E Co-localization of FGFR2 (red), EGFR (green) and the recycling marker Tf (blue) in T47D depleted of EGFR by siRNA followed by transfection with wt or T693A and
stimulated or not with either FGF10 or TGFα for the indicated time periods. Scale bar, 5 μm.
F Red and green pixels overlap fraction representing the co-localization of FGFR2 with EGFR; far-red and green pixels overlap fraction representing the co-localization
of EGFR with the recycling marker Tf; red and far-red pixels overlap fraction representing the co-localization of FGFR2 with the recycling marker Tf; green, red and
far-red pixels overlap fraction representing the co-localization of FGFR2, EGFR and the recycling marker Tf in cells stimulated for 20, 40 or 60 min. with FGF10 or
TGFα. Values represent the median  SD of at least 3 independent experiments. Representative pictures are shown in E. *P < 0.005 (Student’s t-test).
G Lysates from T47D depleted of EGFR by siRNA followed by transfection with siRNA-resistant wt or T693A and stimulated or not with either FGF10 or TGFα for the
indicated time periods were used for immunoprecipitation of FGFR2 and then immunoblotted with the indicated antibodies. The inputs are shown in Appendix Fig
S6F.
H The presence (total), internalization (internalized) and recycling (cell surface) of FGFR2 in T47D depleted of EGFR by siRNA followed by transfection with wt or T693A
and stimulated with FGF10 for different time periods were quantified as described (Francavilla et al, 2016) and in the section ‘Quantification of the Recycling Assay’.
Briefly, we assessed approximately 100 cells per condition and expressed the results as the percentage of receptor-positive cells over total cells (corresponding to
DAPI-stained nuclei) and referred to the values obtained at time zero. Values represent the median  SD of N = 3. *P < 0.005 (Student’s t-test).
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Figure 6. EGFR_T693 phosphorylation controls CDK1 phosphorylation.
A Experimental design of MS-based quantitative phosphoproteomics analysis of wt- and T693A-expressing T47D cells stimulated with FGF10 for 40 or 60 min.
B Hierarchical clustering of the phosphorylated sites differentially quantified in wt- and T693A-expressing T47D stimulated or not with FGF10 for 40 or 60 min. Four
clusters for plasma membrane response (PMR), acquired response (AR), late response (LR), and T693 phosphorylation-dependent response (PDR) are highlighted
with black lines and colour-coded on the right with blue, medium or dark blue and yellow, respectively. The intensity of phosphorylated sites is presented on the
logarithmic scale with intensity below and above the mean colour-coded in blue and red, respectively.
C KEGG pathways enriched in each cluster.
D STRING-based and Cytoscape-visualized network of phosphorylated kinases colour-coded based on clusters shown in Fig 6C. The border of known regulatory sites
is coloured in burgundy. The shape depends on the known function of the regulatory site.
E, F Lysates from T47D (E) and BT20 (F) depleted of EGFR, transfected with wt or T693A, and stimulated or not with either FGF10 or TGFα for the indicated time
intervals were immunoblotted with the indicated antibodies.
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(Stallaert et al, 2018), and the mechanisms which modulate EGFR
activity with strong implications for RTK signalling integration. This
concept is also supported by data showing that EGF-mediated phos-
phorylation of FGFR1 can be a route of RTK cooperation (Zakr-
zewska et al, 2013). Hence, further comprehensive studies are
needed to fully understand how RTKs act in concert in vivo in
response to the simultaneous presence of multiple ligands and how
they ultimately regulate cell fate.
The dynamics of RTK trafficking is affected by several factors and
in turns affects downstream signalling. For instance, EGFR recycles
through recycling endosomes even in the absence of stimuli (Baum-
dick et al, 2015) and can be found in a subset of perinuclear compart-
ments (Tomas et al, 2015). This potentially explains why the
majority of EGFR_T693 phosphorylation is found at recycling endo-
somes upon FGF10 stimulation between 20 and 40 min, a time point
when FGFR2b itself starts accumulating in the recycling endosomes.
In turn, FGFR2b trafficking is deregulated when EGFR remains at the
plasma membrane, e.g. in the absence of T693 phosphorylation,
suggesting that the transient formation of the EGFR/FGFR2b
complex on recycling endosomes is the key regulatory event for the
correct timing of FGFR2b trafficking. One alternative model is that
FGFR2b is internalized, traffics back to the plasma membrane where
it retrieves EGFR, then reinternalizes (potentially recycling together
EGFR), but the reinternalization step stalls without phosphorylation
at T693. Another possibility is that FGFR2b phosphorylates the EGFR
to prevent its recycling to the plasma membrane, thus explaining the
change in EGFR distribution. This process should be replicated in
FGF7-stimulated cells and would require further validation by high-
resolution imaging of pools of FGFR2b and EGFR from the plasma
membrane to recycling endosomes and back. The phosphorylation
of EGFR might delay FGFR recycling back to the plasma membrane,
thus allowing the formation of specific signalling complexes at the
recycling endosomes. The kinases AKT and PAK1 identified by the
three TPAs experiments would be interesting candidates to focus on
to test this hypothesis. The alteration of the kinase landscape shown
in T693A-expressing cells (Fig 6D) also confirms the idea that the
EGFR phosphorylation may work as a scaffold for the recruitment of
recycling machinery (e.g. RCP) and signalling partners to FGFR2b.
The hypothesis of a multi-step regulation of FGFR2b—and possibly
other RTKs—recycling is supported by our data on TTP and RCP.
FGFR2b was not detected in recycling endosomes in TTP-depleted
cells (Fig 1H); therefore, we propose that TTP is required for FGFR2b
entry into recycling endosomes in epithelial cells (Fig 1I) (Francav-
illa et al, 2013). This would explain the lack of T693 phosphorylation
and FGFR2b degradation in the absence of TTP. The third player in
the complex regulation of FGFR2b recycling is RCP, which is bound
to FGFR2b and EGFR in the recycling endosomes. As FGFR2b local-
ized to recycling endosomes in RCP-depleted cells (Fig 1H), but it is
partially degraded in this condition (Fig 1I), RCP may play a role in
FGFR2b exit from recycling endosomes. Therefore, RCP plays a
temporally unique role in FGFR2b trafficking besides being a regula-
tor of EGFR and integrin recycling (Caswell & Norman, 2008; Fran-
cavilla et al, 2016). We speculate on the presence of different
populations of endosomes, either leading to recycling to plasma
membrane (RCP-positive) or to receptor degradation (RCP-negative),
implying that different families of RTKs regulate each other traf-
ficking and signalling through a pool of adaptors on recycling endo-
somes. Future studies will reveal these adaptors upon different
perturbations to build a more comprehensive regulatory network of
RTK trafficking.
RTK recycling is known to control cellular responses, including
proliferation, migration and invasion (Caswell & Norman, 2008;
Francavilla et al, 2013; Francavilla et al, 2016). Here, we show that
the multi-layered regulation of FGFR2b by ligand nature, trafficking
route and EGFR priming fine-tunes downstream responses. Whereas
cell migration and invasion require a signal from FGFR2b in recy-
cling endosomes (Francavilla et al, 2013), the signal to fully promote
the cell cycle occurs in a precise time window, when FGF10 primes
FGFR2b and EGFR to recycling endosomes. As in the absence of the
FGFR/EGFR reciprocal priming growth factors are less mitogenic but
remain pro-migratory, we propose that recycling endosomes are
dynamic signalling hubs that enable cells to coordinate cell cycle
progression and cell invasion in response to multiple growth factors.
Therefore, modulating RTK communication at early time windows
might be an efficient way to re-direct cellular responses in vivo.
The simultaneous presence of RTKs has been described in breast
cancer (Butti et al, 2018), where it might account for response to
combined therapies (Issa et al, 2013), acquired resistance (Hanker
et al, 2017) and epithelial cell-stroma communication (Wu et al,
2018). However, the concept of reciprocal priming has not been
explored yet. It might have implications in TNBC, where both
FGFRs and EGFR are highly expressed (Butti et al, 2018). Although
we have not tested the effect of T693 phosphorylation in normal
breast cells or in the stroma (Weber et al, 2005), this phosphory-
lated site may become a prognostic or predictive marker, if a corre-
lation between T693 phosphorylation, clinical parameters and the
response to combined EGFR/FGFR therapies is determined. This
idea is supported by the detection of T693 phosphorylation in 50%
of the TNBC patient-derived samples analysed in two independent
phosphoproteomic datasets (Mertins et al, 2016; Huang et al, 2017).
Importantly, reciprocal priming of RTKs may have implications
when only one receptor is targeted as part of personalized therapies,
where knock on effects to other pathways are not explored until
resistance mechanisms have arisen (Tan et al, 2017). Targeting pan
RTK trafficking (Porebska et al, 2018) and trafficking players, like
TTP, RCP, and those identified by TPAs might open up novel thera-
peutic scenarios for treatment. Indeed, most of the recycling players
identified here are mutated in breast cancer according to the
◀ Figure 7. FGF10-induced cell cycle progression depends on EGFR_T693 phosphorylation.
A–D Percentage of EdU incorporation in T47D (A, C) or BT20 (B, D) depleted of EGFR or not, transfected with wt or T693A, and stimulated or not with FGF10 (A, B) or
with TGFα (C, D) and pre-treated (C, D) or not (A, B) with FGF10 for 40 min. Values represent the median  SD of N = 4. P =< 0.05*, < 0.01**, < 0.001*** (one-
way ANOVA with Tukey test).
E Relative invasion of wt- or T693A-transfected BT20 cells into fibronectin-supplemented collagen I was quantified as described in Material and Methods. Graph
depicts mean  SEM of N = 8. *P =< 0.05 (Student’s t-test).
F Representative images of E. Black indicates cells. Confocal depth is indicated between panels. Scale bar, 250 μm. oe, overexpression.
G Model of reciprocal priming between FGFR and EGFR, based on this study.
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COSMIC database (Tate et al, 2019) and the importance of traf-
ficking proteins in breast cancer is emerging (Wittkowski et al,
2018).
Understanding the extent of RTK regulation “in the right place at
the right time” (Barrow-McGee & Kermorgant, 2014) is key for the
integration of early signalling and long-term responses in cancer
cells. Here, we unveiled a new form of RTK communication, a recip-
rocal priming coordinated from the recycling endosomes. Thus, the
integration of TPAs offers a wealth of new candidates to investigate
the functional consequences of trafficking-mediated signalling and
has the potential to guide individualized treatment in cancer and
other disease (Butti et al, 2018; Kobayashi et al, 2020).
Material and Methods
Materials availability
Further information and requests for resources and reagents should be directed to and will be fulfilled by Chiara Francavilla by email at
chiara.francavilla@manchester.ac.uk.
Reagents and Tools table
This information is provided in a separate Reagents and Tools Table.
Reagent or Resource Source Identifier
Antibodies
Rabbit anti Phospho-EGF Receptor (Tyr1068) Antibody Cell Signaling Technology 2234S
Mouse monoclonal Phospho-p38 MAPK (Thr180/Tyr182) (28B10) Cell Signaling Technology 9216S
Rabbit polyclonal CDK1 (phospho T161) Abcam ab47329-100ug
Rabbit polyclonal CDK1 Abcam ab131450-100ug
Mouse monoclonal FIP1/RCP antibody Bio Techne NBP2-20033
Mouse monoclonal ERK 1/2 Santa Cruz Biotechnology sc-135900
Mouse monoclonal γ-Tubulin Sigma-Aldrich T5326
Mouse monoclonal Vinculin Sigma Aldrich V9264-200UL
Rabbit polyclonal pEGFR Thr669 Cell Signaling Technology 3056s
Rabbit monoclonal pEGFR Thr669 Cell Signaling Technology 8808s
Rabbit monoclonal p44/42 MAPK (Erk1/2) (137F5) Cell Signaling Technology 4695S
Mouse monoclonal GAPDH Abcam ab8245-100ug
Mouse monoclonal EGFR (Ab-1) Merck GR01L-100UG
Rabbit polyclonal EGFR millipore 06-847
Rabbit monoclonal FGFR1 antibody D8E4 Cell Signaling Technology 9740
Rabbit polyclonal SH3BP4 Abcam PLC ab106609-100ug
Rabbit monoclonal FGF Receptor 2 (D4L2V) Cell Signaling Technology 23328S
Rabbit monoclonal P38 Cell Signaling Technology 9212
Rabbit monoclonal GFP Cell Signaling Technology 2956
Peroxidase-AffiniPure F(ab’)2 Fragment Goat Anti-Mouse IgG (H + L) (min X
Hu, Bov, Hrs Sr Prot)
Stratech 115-036-062-JIR-0.5ml
Peroxidase-AffiniPure F(ab&#39;)2 Fragment Goat Anti-Rabbit IgG (H + L)
(min X Hu Sr Prot)
Stratech 111-036-045-JIR-0.5m
Mouse monoclonal to EEA1 BD Bioscience 610457
Goat anti-Rabbit IgG (H + L) Secondary Antibody, Alexa Fluor® 488 conjugate Invitrogen A11034
Goat anti-Mouse IgG (H + L) Secondary Antibody, Alexa Fluor® 488 conjugate Invitrogen A11001
Goat anti-Rabbit IgG (H + L) Secondary Antibody, Alexa Fluor® 568 conjugate Invitrogen A11011
Donkey Anti-Mouse IgG (H + L) Secondary Antibody, Alexa Fluor® 647
conjugate
Invitrogen A31571
Donkey Anti-Rabbit IgG (H + L) Secondary Antibody, Alexa Fluor® 647
conjugate
Invitrogen A31573
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Reagents and Tools table (continued)
Reagent or Resource Source Identifier
Bacterial and Virus Strains
NEB® 10-beta Competent E. coli (High Efficiency) New England Biolabs Cat. No: C3019H
Biological Samples
Chemicals, Peptides, and Recombinant Proteins
Trypsin porcine pancreas (proteomics grade) Sigma-Aldrich T6567
Lysyl Endopeptidase FUJIFILM Wako Chemicals 2541
TiO beads “Titanspheres” GL Sciences 5020-75000
Pre-cast gradient gel: Nu-PAGE 4-12% Bis-Tris Gel 1.0mm 10 well Invitrogen NP0321BOX
Sep-Pak Classic C18 cartridges Waters WAT051910
Solid Phase Extraction Disk “Empore” C18 (Octadecyl) 3 M Agilent Technologies 2215
Solid Phase Extraction Disk “Empore” C8 (Octyl) 3 M Agilent Technologies 2214
L-ARGININE:HCL Cambridge Isotope Laboratories CLM-2265-H-0.25
L-ARGININE:HCL Cambridge Isotope Laboratories CNLM-539-H-0.5
L-ARGININE:HCL Sigma-Aldrich A6969
L-LYSINE:2HCL Cambridge Isotope Laboratories DLM-2640-0.5
L-LYSINE:2HCL Cambridge Isotope Laboratories CNLM-291-H-0.5
L-LYSINE:2HCL Sigma-Aldrich L8662
2,5-Dihydroxybenzoic acid Sigma-Aldrich 85707
RPMI 1640 Medium for SILAC ThermoFisher Scientific 88365
TRIzol™ Reagent ThermoFisher Scientific Cat. No. 15596026
DIHYDROETHIDIUM Cambridge Bioscience 12013-5mg-CAY
Hoechst 33342 New England Biolabs 4082S
Lipofectamine RNAiMAX Transfection Reagent ThermoFisher Scientific 10601435
Lipofectamine Transfection Reagent Life Technologies 18324020
FuGENE HD Transfection Reagent Promega UK E2311
Sodium Pyruvate solution 100mM (100ml) Sigma-Aldrich S8636-100ML
Crystal violet solution Sigma-Aldrich V5265-250ML
Carestream Kodak BioMax MR Film Kodak Z350370-50EA
Xtra-Clear Flat 8-Strip Caps Star labs I1400-0900-C
96-Well PCR Plate Non-Skirted Low Profile Natural Star labs E1403-0200-C
RPMI 1640 Medium Glutamax Supplement (500ml) Gibco 61870010
ReliaPrep RNA Cell Miniprep System NEB Z6011
Color Prestained Protein Standard Broad Range NEB P7712S
Prestained Protein Standard Broad Range Sigma-Aldrich SDS7B2
PURELINK QUICK MINI NEB? K210010
T4 DNA Ligase 20,000 u NEB? M0202S
DMEM High glucose HEPES w/o Glutamine and Sodium pyruvate Sigma-Aldrich D6171-6X500ML
DMEM AQ medium Sigma-Aldrich D0819-500ml
RPMI 1640 w/L-Glutamine-Bicarbonate Sigma-Aldrich R8758-6X500ML
Q5 High Fidelity 2x mastermix NEB M0492S
Nutrient Mix F12 HAM Sigma-Aldrich N6658-500ML
Human EGF (Animal Free) PeproTech AF-100-15-1000
PRESTAINED MOLECULAR WEIGHT MARKER, MW 2 Sigma-Aldrich SDS7B2-1VL
MG132 Fisher Sientific 15465519
HYPERFILM ECL 18X24CM VWR International Ltd 28-9068-37
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Reagents and Tools table (continued)
Reagent or Resource Source Identifier
Albumin, Bovine Fraction V (BSA), 100 Grams Cat No: A30075-100.0 Melford Biolaboratories Ltd A30075-100.0
Bradford Reagent Bio-Rad 5000205
Clarity ECL Bio-Rad 1705061
GoScript Reverse Transcription Mix, Random Primers Promega A2801
Pierce Protease Inhibitor Tablets-20 tablets Life Tehnologies A32963
MEMBRANE PROTRAN 0,45uM NC 300MMX4 M VWR 10600002
qPCRBIO SyGreen Mix Separate-ROX pcr biosystems PB20.14-50
ProLong Diamond Antifade Mountant-2 mL Life Technologies P36965
ExoSAP-IT Life Technologies 78250.40.ul
DMSO Sigma-Aldrich 276855-250ml
ACETONITRILE VWR International Ltd 1.00030.2500
HEPARIN SODIUM CELL CULTURE TESTED Sigma-Aldrich H3149-100KU
Escort IV SLS L3287-1ML
Penicillin-Streptomycin (10,000 U/mL) Life Technologies Ltd 15140122
Human EGF Sigma-Aldrich E9644-.2MG
Human TGFα Pepro Tech Limited 100-16A
Human FGF1 Pepro Tech Limited 100-17A-50
Human FGF7 Francavilla et al 2013 PI: Prof Olsen
Human FGF3 Bio Techne 1206-F3-025
Human FGF10 Francavilla et al 2013 PI: Prof Olsen
Enkamin-E Pepro Tech Limited A14-529EP
PD173074 Selleckchem S1264
AG1478 Cell Signalling Technologies 9842
U2106 Cell Signalling Technologies 9903
MEK162 APEXBIO A1947
BMS582949 Selleck Chem S8124
Collagen I, HC, Rat Tail, 100 mg Corning 354249
FIBRONECTIN FROM BOVINE PLASMA Sigma F1141-1MG
DMEM powder, high glucose Thermo Fisher 52100021
Fetal Bovine Serum, South American origin Life Technologies 10270106
TW PC MEMBRANE,6.5MM,8.0UM Transwell Inserts Sigma Aldrich CLS3422-48EA
Calcein AM cell permanent Dye Fisher Scientific C1430
Glacial Acetic Acid (HPLC Grade) Fisher Scientific UK 10060000
Formic Acid (HPLC Grade) Sigma-Aldrich 5438040250
Trifluoracetic Acid (Spectroscopy Grade) Sigma-Aldrich 1082621000
Dispase Stem Cell Technologies 7913
Matrigel Corning 354230
DAPI (4’,6-Diamidino-2-Phenylindole, Dihydrochloride) Life Technology D1306
Transferrin From Human Serum, Alexa Fluor™ 647 Conjugate Invitrogen T23366
Transferrin From Human Serum, Tetramethylrhodamine Conjugate Invitrogen T2872
Critical Commercial Assays
Click-iT EdU Alexa Fluor 488 Imaging Kit-1 kit Life Technologies C10337
Venor®GeM Classic Mycoplasma PCR Detection Kit(100 tests) Cambridge Bioscience 11-1100
ProtoScript; II First Strand cDNA Synthesis Kit New England Biolabs E6560L
ReliaPrep RNA Cell Miniprep System Promega Z6011
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Reagents and Tools table (continued)
Reagent or Resource Source Identifier
Tumor dissociation kit Miltenyi Biotec 130-095-929
Isolate II PCR and Gel kit Bioline BIO-52059
Isolate II plasmid mini kit Bioline BIO-52056
Deposited Data
Raw data (MS) This paper http://proteomecentral.proteomexc
hange.org/cgi/GetDataset (dataset
identifier PXD018184)
Experimental Models: Cell Lines
MCF-7 LGC ATCC® HTB-22
MDA-MB-415 LGC ATCC® HTB-24
BT20 LGC ATCC® HTB-19
HCC1937 LGC ATCC® CRL-2336
T47D LGC ATCC® HTB-133
BT549 LGC ATCC® HTB-122
Experimental Models: Organisms/Strains
BB6RC37 Eyre et al (2016) PI: R. Clarke
Oligonucleotides







CGGAAUAGGUAUUGGUGAAUUUAAA Invitrogen EGFRHSS176346 (G01)
CCUAUGCCUUAGCAGUCUUAUCUAA Invitrogen EGFRHSS103116 (G06)
CCCGUAAUUAUGUGGUGACAGAUCA Invitrogen EGFRHSS103114 (G09)
CCN1 F- GGTCAAAGTTACCGGGCAGT R- GGAGGCATCGAATCCCAGC In house n/a
DUSP1 F- GCCTTGCTTACCTTATGAGGAC R-GGGAGAGATGATGCTTCGCC In house n/a
FOS F- AGGAGGGAGCTGACTGATACACT R- TTTCCTTCTCCTTCAGCAGGTT In house n/a
JUNB F- ACGACTCATACACAGCTACGG R- GCTCGGTTTCAGGAGTTTGTAGT In house n/a
TIMP3 F- CATGTGCAGTACATCCATACGG R- CATCATAGACGCGACCTGTCA In house n/a
EGR1 F- GAGAAGGTGCTGGTGGAGAC R- CACAAGGTGTTGCCACTGTT In house n/a
BCL10 F- GTGAAGAAGGACGCCTTAGAAA R- TCAACAAGGGTGTCCAGACCT In house n/a
CTGF F- CAGCATGGACGTTCGTCTG R- AACCACGGTTTGGTCCTTGG In house n/a
MCL1 F-ATCTCTCGGTACCTTCGGGAGC R- GCTGAAAACATGGATCATCACTCG In house n/a
DUSP6 F- CCGCAGGAGCTATACGAGTC R- CGTAGAGCACCACTGTGTCG In house n/a
ABHD5 F- GCTGCTGCTTACTCGCTGAA R- TCTGATCCAAACTGGAATTGGTC In house n/a
KDM6B F- CACCCCAGCAAACCATATTATGC R- CACACAGCCATGCAGGGATT In house n/a
MXD1 F- CGTGGAGAGCACGGACTATC R- CCAAGACACGCCTTGTGACT In house n/a
NDRG1 F CTCCTGCAAGAGTTTGATGTCC - R- TCATGCCGATGTCATGGTAGG In house n/a
SPRY2 F- CCTACTGTCGTCCCAAGACCT R- GGGGCTCGTGCAGAAGAAT In house n/a
ID4 F- TGCCTGCAGTGCGATATGAA R- GCAGGTCCAGGATGTAGTCG In house n/a
FGFR2b F- AACGGGAAGGAGTTTAAGCAG R- CTCGGTCACATTGAACAGAG In house n/a
BETA ACTIN F- TGGAACGGTGAAGGTGACAG R- AACAACGCATCTCATATTTGGAA In house n/a
GAPDH F- CAATGACCCCTTCATTGACC R- GACAAGCTTCCCGTTCTCAG In house n/a
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Reagents and Tools table (continued)
Reagent or Resource Source Identifier
Recombinant DNA
EGFR (pRK5-EGFR) Addgene Plasmid #65225
EGFRT693A Mutagenesis of above
eGFP-Rab11 Addgene Plasmid #12674
eGFP-Rab11_S52N Mutagenesis of above
Dynamin_K44a-eGFP Mutagenesis of Addgene plasmid Plasmid # 34680
HA-FGFR1c Francavilla et al (2009) PI: Dr Cavallaro
HA-FGFR2b Francavilla et al (2013) PI: Prof Olsen
HA_FGFR2b_Y656F/Y657F Francavilla et al (2013) PI: Prof Olsen
HA-FGFR4 cloned using human cDNA with primers F-
GGGGCCCAGCCGGCCAGACTGGAGGCCTCTGAGGAAGTGGAGCTTGAGCC R -
GTCGACCTGCAGTGTCTGCACCCCAGACCCGAAGGGGAAGGAGCTGGATCC
Generated for this study n/a
Software and Algorithms
Fiji- Image J version: 1.52p Schindelin et al (2012) https://imagej.net/Fiji
GraphPad Prism version 8.0.0 GraphPad Software www.graphpad.com
MaxQuant version 1.5.6.5 Cox and Mann (2008) http://www.coxdocs.org/doku.php?
id=maxquant:start
WebGestalt 2019 Liao et al (2019) http://www.webgestalt.org/
Perseus versions 1.6.5.0 or 1.6.2.1.: Tyanova et al (2016) http://www.coxdocs.org/doku.php?
id=maxquant:start
Cytoscape version 3.7.2 Shannon et al (2003) https://www.cytoscape.org
STRING version 11 Szklarczyk et al (2019) https://string-db.org/
R framework R Core Team (2018) https://www.r-project.org/
Other
Confocal Microscope Leica Sp8 Inverted Lecia
Mx3000P qPCR machine Agilent
UltiMate® 3000 Rapid Separation LC Dionex
QE-HF LC-MS/MS Thermo Fisher Scientific
Methods and Protocols
Experimental models
Cell culture and SILAC labelling
Human breast cancer cell lines were purchased from ATCC, authen-
ticated through short tandem repeat (STA) analysis of 21 markers
by Eurofins Genomics, checked monthly for mycoplasma via a PCR-
based detection assay (Venor®GeM—Cambio) and grown in the
indicated media supplemented with 2 mM L-glutamine and 100 U/
ml penicillin, 100 μg/ml streptomycin, and 10% foetal bovine
serum. MCF-7 was grown in DMEM/F12. MDA-MB-415 and BT20
were grown in DMEM. HCC1937, T47D and BT549 were grown in
RPMI. 1 mM sodium pyruvate was added to T47D.
For quantitative mass spectrometry, BT549 or T47D cells were
labelled in SILAC RPMI (PAA Laboratories GmbH, Germany)
supplemented with 10% dialyzed foetal bovine serum (Sigma),
2 mM glutamine (Gibco), 100 U/ml penicillin and 100 μg/ml strep-
tomycin for 15 days to ensure complete incorporation of amino
acids, which was verified by MS analysis. Three cell populations
were obtained: one labelled with natural variants of the amino acids
(light label; Lys0, Arg0), the second one with medium variants of
amino acids (medium label; L-[13C6] Arg (+6) and L-[2H4]Lys
(+4); Lys4/Arg6) and the third one with heavy variants of the
amino acids (heavy label; L-[13C6,15N4]Arg (+10) and L-
[13C6,15N2]Lys (+8); Lys8/Arg10). The light amino acids were
from Sigma, whilst their medium and heavy variants were from
Cambridge Isotope Labs (Massachusetts, US).
Breast cancer organoid culture and protein isolation
Organoids were generated from a triple-negative breast cancer PDX
tumour, BB6RC37 (Eyre et al, 2016). The tumours were minced and
digested using a tumour dissociation kit (Miltenyi Biotec) on an
orbital shaker at 37°C for 1–2 h. The cells were sequentially strained
through 100-µm and 40-µm meshes. 50,000 cells were resuspended
in 50 µl cold growth factor-reduced Matrigel (Corning 354230), set
as domes in a 24-well plate for 30 min and cultured at 37°C in
media as defined by (Sachs et al, 2018). The organoids were
cultured in media with or without FGF7/10 for 14 days, and EGF/
Heregulin were removed from the media 24 h before lysates were
obtained. Lysates were prepared by mechanically disaggregating the
domes and digesting the Matrigel for 1 h using dispase at 37°C
(Stem Cell Technologies, 7913). Cells were washed in PBS and
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resuspended in lysis buffer as previously described (Santiago-
Gomez et al, 2019).
Quantitative phosphoproteomics
Experimental design and sample preparation
TPA1: for each cell line and each stimulus, we analysed duplicates
for each time point, considering both 1- and 8-min. time points as
representative of early signalling. Therefore, we compared four
label-free samples for each stimulus in each cell line (Datasets EV1
and EV2). The cell pellet was dissolved in denaturation buffer
(6 M urea, 2 M thiourea in 10 mM HEPES pH 8). We obtained
1 mg of proteins from each sample. Cysteines were reduced with
1 mM dithiothreitol (DTT) and alkylated with 5.5 mM chloroac-
etamide (CAA). Proteins were digested with endoproteinase Lys-C
(Wako, Osaka, Japan) and sequencing grade modified trypsin
(modified sequencing grade, Sigma) followed by quenching with
1% trifluoroacetic acid (TFA). Peptides were purified using
reversed-phase Sep-Pak C18 cartridges (Waters, Milford, MA) and
eluted with 50% acetonitrile (ACN). After removing ACN by
vacuum concentrator at 60°C, peptides were suspended in phos-
phopeptide immunoprecipitation buffer (50 mM MOPS pH 7.2,
10 mM sodium phosphate, 50 mM NaCl) and dissolved overnight.
Clarified peptides were transferred in a new tube containing
immobilized phosphorylated tyrosine antibody beads (pY100-AC,
Cell Signalling Technologies) and incubated for two hours at 4°C.
After five washes with immunoprecipitation buffer followed by
two washes with 50 mM NaCl, the enriched peptides were eluted
from the beads three times with 50 μL of 0.1% TFA, loaded on
C18 STAGE-tips, and eluted from STAGE-tips with 20 μL of 40%
ACN followed by 10 μL 60% ACN and reduced to 5 μL by
SpeedVac and 5 μL 0.1% formic acid (FA) 5% ACN added.
Peptides from the supernatant were purified using reversed-phase
Sep-Pak C18 cartridges (Waters, Milford, MA) and eluted with
50% ACN and further enriched for phosphorylated serine- and
phosphorylated threonine-containing peptides, with Titansphere
chromatography. Six mL of 12% TFA in ACN was added to the
eluted peptides and subsequently enriched with TiO2 beads
(5 μm, GL Sciences Inc., Tokyo, Japan). The beads were
suspended in 20 mg/mL 2,5-dihydroxybenzoic acid (DHB), 80%
ACN, and 6% TFA and the samples were incubated in a sample
to bead ratio of 1:2 (w/w) in batch mode for 15 min with rota-
tion. After 5-min centrifugation, the supernatant were collected
and incubated a second time with a twofold dilution of the previ-
ous bead suspension. The beads were washed with 10% ACN,
6% TFA followed by 40% ACN, 6% TFA and collected on C8
STAGE-tips and finally washed by 80% ACN, 6% TFA. Elution of
phosphorylated peptides was done with 20ul 5% NH3 followed
by 20 μL 10% NH3 in 25% ACN, which were evaporated to a
final volume of 5 μL in a sped vacuum. The concentrated phos-
phorylated peptides were acidified with addition of 20 μL 0.1%
TFA, 5% ACN and loaded on C18 STAGE-tips. Peptides were
eluted from STAGE-tips with 20 μL of 40% ACN followed by 10
μL 60% ACN and ACN and reduced to 5 μL by SpeedVac and 5
μL 0.1% FA, 5% ACN added.
A small amount of the eluted peptides (1%) was taken for
proteome analysis before enrichment of phosphorylated peptides:
after evaporation in a speed vacuum, 40 μl of 0.1% TFA, 5% ACN
were added followed by MS analysis.
TPA2: we analysed label-free triplicates for each condition,
T47D depleted or not of TTP or RCP and stimulated or not with
FGF10. Cells were washed with PBS and lysed at 4°C in ice-cold
1% triton lysis buffer supplemented with Pierce protease inhibitor
tablet (Life Technologies) and phosphatase inhibitors: 5 nM
Na3VO4, 5 mM NaF and 5 mM β-glycerophosphate. Proteins were
precipitated overnight at −20°C in fourfold excess of ice-cold
acetone. The acetone-precipitated proteins were solubilized in
denaturation buffer (10 mM HEPES, pH 8.0,6 M urea, 2 M
thiourea), and 5 mg of proteins was reduced, alkylated and
digested, as described above. All the steps were performed at room
temperature. The peptide mixture was desalted and concentrated
on a C18-Sep-Pak cartridge, eluted and enriched with TiO2 beads,
as described above.
TPA3: we analysed duplicates of SILAC-labelled BT549, trans-
fected and treated as described in Fig 2A. We followed the same
procedure described for TPA2 with the only difference that 5 mg of
each SILAC-labelled lysates was mixed in equal amount before
digestion and TiO2 chromatography.
EGFR- and EGFR_T693A-expressing T47D cells: we analysed
duplicates of SILAC-labelled T47D transfected and treated as
described in Fig 6A. We followed the same procedure described for
TPA1 with the only difference that 5 mg of each SILAC-labelled
lysates was mixed in equal amounts before digestion and phospho-
rylated tyrosine enrichment followed by TiO2 chromatography and
peptides purification.
Mass spectrometry
Purified peptides were analysed by LC-MS/MS using an UltiMate®
3000 Rapid Separation LC (RSLC, Dionex Corporation, Sunnyvale,
CA) coupled to a QE-HF (Thermo Fisher Scientific, Waltham,
MA) mass spectrometer. Mobile phase A was 0.1% FA in water,
and mobile phase B was 0.1% FA in ACN and the column was a
75 mm x 250 μm inner diameter 1.7 μM CSH C18, analytical
column (Waters). A 1 μl aliquot of the sample (for proteome
analysis) or a 3 μl aliquot was transferred to a 5 μl loop and
loaded on to the column at a flow of 300 nl/min at 5% B for 5
and 13 min, respectively. The loop was then taken out of line
and the flow was reduced from 300 nl/min to 200nl/min in
1 min., and to 7% B. Peptides were separated using a gradient
that went from 7% to 18% B in 64 min., then from 18% to 27%
B in 8 min. and finally from 27% B to 60% B in 1 min. The
column was washed at 60% B for 3 min. and then re-
equilibrated for a further 6.5 min. At 85 min, the flow was
increased to 300nl/min until the end of the run at 90min. Mass
spectrometry data were acquired in a data directed manner for
90 min in positive mode. Peptides were selected for fragmentation
automatically by data-dependent analysis on a basis of the top 8
(phosphoproteome analysis) or top 12 (proteome analysis) with
m/z between 300 and 1750Th and a charge state of 2, 3 or 4
with a dynamic exclusion set at 15 s. The MS resolution was set
at 120,000 with an AGC target of 3e6 and a maximum fill time
set at 20ms. The MS2 resolution was set to 60,000, with an AGC
target of 2e5, and a maximum fill time of 110 ms for Top12
methods, and 30,000, with an AGC target of 2e5, and a maxi-
mum fill time of 45 ms for Top8 analysis. The isolation window
was of 1.3Th (2.6 Th for SILAC-labelled samples), and the colli-
sion energy was of 28.
20 of 26 The EMBO Journal e107182 | 2021 ª 2021 The Authors
The EMBO Journal Michael P Smith et al
Raw files analysis
Raw data were analysed by the MaxQuant software suite (Cox &
Mann, 2008) (https://www.maxquant.org; version 1.5.6.5) using
the integrated Andromeda search engine (Cox et al, 2011). Proteins
were identified by searching the HCD-MS/MS peak lists against a
target/decoy version of the human UniProt Knowledgebase database
that consisted of the complete proteome sets and isoforms (v.2016;
https.//uniprot.org/proteomes/UP000005640_9606) supplemented
with commonly observed contaminants such as porcine trypsin and
bovine serum proteins. Tandem mass spectra were initially matched
with a mass tolerance of 7 ppm on precursor masses and 0.02 Da or
20 ppm for fragment ions. Cysteine carbamidomethylation was
searched as a fixed modification. Protein N-acetylation, N-pyro-
glutamine, oxidized methionine and phosphorylation of serine, thre-
onine and tyrosine were searched as variable modifications. Protein
N-acetylation, oxidized methionine and deamidation of asparagine
and glutamine were searched as variable modifications for the
proteome experiments. For the quantification of SILAC-labelled
samples, labelled lysine and arginine were specified as fixed or vari-
able modification, depending on prior knowledge about the parent
ion (MaxQuant SILAC triplet identification). In all the other experi-
ments, label-free parameters were used as described (Cox et al,
2014). False discovery rate was set to 0.01 for peptides, proteins and
modification sites. Minimal peptide length was six amino acids. Site
localization probabilities were calculated by MaxQuant using the
PTM scoring algorithm (Olsen et al, 2006). The datasets were fil-
tered by posterior error probability to achieve a false discovery rate
below 1% for peptides, proteins and modification sites. Only
peptides with Andromeda score > 40 were included.
Data and statistical analysis
All statistical and bioinformatics analyses were done using the freely
available software Perseus, version 1.6.5.0 or 1.6.2.1. (Tyanova &
Cox, 2018), R framework (R Core Team, 2018), Bioconductor R-
package LIMMA (Bolstad et al, 2003), WebGestalt (Liao et al, 2019),
STRING (Szklarczyk et al, 2019), Cytoscape (version 3.7.2) (Shan-
non et al, 2003). All measured peptide intensities were normalized
using the “normalizeQuantiles” function from the Bioconductor R-
package LIMMA, which normalizes the peptide intensities such that
each quantile for each sample is set to the mean of that quantile
across the dataset, resulting in peptide intensity distributions that
are empirically identical. Each dataset was normalized individually.
Subsequent data analysis was performed using Microsoft Office
Excel, R and Perseus. For the SILAC datasets, we used the normal-
ized SILAC ratios from MaxQuant output txt files. Only peptides
with localization probabilities higher than 0.75 (class I, shown in
Datasets EV1, EV3–EV6; Olsen et al, 2006) were included in the
downstream bioinformatics analysis. Pearson correlation was calcu-
lated in R. For TPA1, we impute missing values using Perseus
default settings, we subtracted the control from log intensity values
in order to be able to compare all the cell lines against each other
and we used the median for each condition. Hierarchical clustering
based on correlation was performed after multi-sample ANOVA test
with default parameters in Perseus. For TPA2, we calculated the
median and then considered only rows with four valid values,
followed by hierarchical clustering based on Euclidean distance in
Perseus. For TPA3 and the EGFR/EGFR_T693A T47D dataset, we
imputed missing values using Perseus default settings and then
calculated the median, followed by hierarchical clustering based on
Euclidean distance in Perseus. Clusters used in the follow-up analy-
sis were defined by Perseus and manually checked.
The enrichment of KEGG or GO terms was performed in WebGes-
talt using the ORA default parameters, and significantly over-
represented terms within the data were represented in bar plots.
The relation of genes to other diseases was based on the database
DISEASES (Pletscher-Frankild et al, 2015).
All the protein interaction networks were obtained using the
STRING protein interaction database using high confidence, and
interactions derived from the Experiments and Databases evidence
channels. Data visualization was performed using the software
Cytoscape. The Venn diagram was created using the web tool http://
bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/calculate_venn.htpl.
Biochemical assays
RNA isolation and real-time PCR analysis
RNA from cell lines was isolated with TRIZOL® (Invitrogen). After
chloroform extraction and centrifugation, 5 µg RNA was DNase
treated using RNase-Free DNase Set (Qiagen) and 1 µg of DNase
treated RNA was then taken for cDNA synthesis using the Proto-
script I first strand cDNA synthesis kit (New England Biolabs).
Selected genes were amplified by quantitative real-time PCR (RT–
qPCR) using Sygreen (PCR Biosystems). Relative expression was
calculated using the delta-delta CT methodology, and beta-actin was
used as reference housekeeping gene. Sequences for primers used
can be found in the accompanying Reagent Table. qPCR machine
used was Applied Biosystems MX300P.
Transfection and RNA interference
All transfections were carried out in Gibco opti-MEM glutamax
reduced serum media (Thermo Fisher Scientific). For RNA interfer-
ence, all cells were transfected using Lipofectamine RNAiMax
(Thermo Fisher Scientific), according to manufacturer instructions.
Validated double-stranded stealth siRNA oligonucleotides were used
for RNA interference. siRNA Universal Negative Control #2 (Sigma-
Aldrich) was used as a control in all RNA interference experiments.
BT549 and BT20 cells were transfected using Lipofectamine 3000
(Thermo Fisher Scientific) according to the manufacturer’s instruc-
tions, 24 h after RNA interference transfection where indicated.
T47D cells were transfected using Escort IV according to manufac-
turer instructions, same as above. Assays were performed 36 h after
transfection, as previously described (Francavilla et al, 2016). Where
assays were performed more than 36 h after transfection, RNAi and
expression were assessed at time of assay to confirm expression.
Cell lysis, protein immunoprecipitation and western blotting
Cells were serum starved overnight in serum-free medium and stim-
ulated for the indicated time points with 100 ng/ml of FGF7, FGF10,
EGF or TGFα. Ligands were replenished every 24 h for long-term
(24–72 h) stimulation. Where indicated, cells were pre-incubated
for 2 h with 100 nM PD173074, 500 nM AG1478, 20 μM U1206,
1 μM MEK162 or 10 μM BMS582949. Control cells were pre-
incubated with DMSO alone. After stimulation, cell extraction
and immunoblotting were performed as previously described (Fran-
cavilla et al, 2016). Proteins were resolved by SDS–PAGE and trans-
ferred to nitrocellulose membranes (Protran, Biosciences). Proteins
of interest were visualized using specific antibodies, followed by
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peroxidase-conjugated secondary antibodies and by an enhanced
chemiluminescence kit (Amersham Biosciences). Blots were visual-
ized either using film exposure or the Universal Hood II Gel Molecu-
lar Imaging System (Bio-Rad). Each experiment was repeated at
least three times and produced similar results.
Immunoprecipitation of FGFR2 from cell extracts was performed
as previously described (Francavilla et al, 2016), using anti BEK
(Santa Cruz Biotechnology, sc-121). Each experiment was repeated
at least three times and produced similar results.
Biotinylation assays
Biotinylation pull down experiments were performed as described
previously (Lobingier et al, 2017). Briefly biotinylation experiments
were performed by transfecting GFP-Rab11-APEX2 constructs in to 2
million cells plated in 10-cm dishes. Cells were pre-incubated (40 min)
with biotin phenol (Iris Biotech), after stimulation with ligands, hydro-
gen peroxide (Sigma-Aldrich) was added for 1 min before quenching
with Trolox (Sigma-Aldrich) and sodium ascorbate (VWR) during ice-
cold lysis. A 2-hour RT pull down with streptavidin beads was then
performed running the supernatant against the bound proteins.
Proliferation assays
Incucyte cell proliferation assay
Indicated cell lines were seeded into 24-well plates at a density of
15,000–20,000 cells per well, depending on growth rate and the
design of the experiment. After plating cells were starved and stimu-
lated with indicated ligands every 24 h and imaged every hour using
the Incucyte ZOOM (Essen Bioscience), phase-contrast images were
analysed to detect cell proliferation based on cell confluence. And
average confluency value over 4 h was used to determine the start-
ing confluency from which a relative growth change was calculated.
Statistical analysis was performed at the endpoint across repeats, as
indicated in the Fig legends.
Crystal Violet
Indicated cells were stained after experimentation by being fixed
with 0.5% w/v crystal violet (Sigma) in 4% w/v paraformaldehyde/
PBS for 30 min. Fixed cells were then solubilized in 2% w/v SDS/
PBS and absorbance measured at 595 nm using Synergy H1 micro-
plate reader (BioTek). Statistical analysis was performed at the
endpoint across repeats, as indicated in the Fig legends.
EdU incorporation
Indicated cells were labelled with 20 µM 5-ethynyl-2’-deoxyuridine
(EdU) for 4 h and processed following the manufacturer’s protocol
(Click-iT® EdU Alexa Fluor® 488 Imaging Kit, Thermo Fisher). Prior
to imaging, cells were then stained with 5 ng/ml Hoecsht 3342 for
15 min. Stained cells were analysed using a using a Leica micro-
scope system. Statistical analysis was performed at the endpoint
across repeats, as indicated in the Fig legends.
Invasion assay
Rat tail-derived collagen I (Corning) was supplemented with 25 µg/
ml human fibronectin (Sigma) in DMEM and polymerized in 8-µm
Transwell inserts (Corning) for 30 min at room temperature followed
by 30 min at 37°C/5% CO2. 5 x 104 BT20 cells were seeded on the
reverse of each insert and incubated for 6 h at 37°C/5% CO2. Inserts
were gently washed and placed in serum-free DMEM and the upper
chamber filled with DMEM supplemented with 10% FCS (Life Tech-
nologies) and either PBS or 100 ng/ml FGF10 (PeproTech). After
72 h, cells were stained with 500 ng/ml Calcein AM (Thermo Fisher)
for 1 h and visualized by Leica Sp8 inverted confocal microscopy in
serial sections of 20 µm. Fluorescence intensity of each section was
determined using ImageJ v. 1.52p (Schindelin et al, 2012) and
proportion of invading cells estimated by comparing the total inten-
sity beyond 40 µm with the total overall intensity per insert using
GraphPad PRISM version 8.0.0. Statistical analysis was performed at
the endpoint across repeats, as indicated in the Fig legends.
Immunofluorescence
Immunofluorescence staining was performed as previously described
(Francavilla et al, 2016). To detect HA-FGFR2b or endogenous FGFR2,
we incubated cells with 10 μg/ml of anti-HA (Covance) or anti-FGFR2
antibody (Cell Signalling) for 45 minutes with gentle agitation. The
binding of the antibody did not activate receptor signalling in
untreated cells nor induced receptor internalization (see control cells
in Fig 1), as previously reported (Francavilla et al, 2009). After stimu-
lation, cells were incubated at 37°C for different time points. When
indicated, each inhibitor was added prior stimulation. At each time
point, non-permeabilized cells were either fixed to visualize the recep-
tor on the cell surface (plasma membrane) or acid-washed in ice-cold
buffer (50 mM glycine, pH 2.5) to remove surface-bound antibody.
Acid-washed cells were then fixed and permeabilized to visualize the
internalized receptor (cytoplasm). Finally, to detect FGFR2b cells were
stained with AlexaFluor488-conjugated donkey anti-mouse or anti-
rabbit (Jackson ImmunoResearch Laboratories). Nuclei were stained
with DAPI. Coverslips were then mounted in mounting medium (Vec-
tashield; Vector Laboratories).
For co-localization experiments, cells were acid-washed, fixed,
permeabilized with 0.02% saponin (Sigma), treated with a primary
antibody against FGFR2, EGFR, TTP, RCP, phosphorylated T693
EGFR, EEA1 for 60 min at 37 °C and stained with AlexaFluor488 (or
568 or 647)-conjugated donkey anti-mouse or anti-rabbit. Samples
either expressing GFP-tagged proteins or treated with TRITC-
transferrin or Alexa 647-transferrin (to stain transferrin receptor, Tf-
R), added to the medium at a final concentration of 50 μg/mL, were
kept in the dark. Nuclei were stained with DAPI. Coverslips were then
mounted in mounting medium (Vectashield; Vector Laboratories).
All the images were acquired at room temperature on a Leica
TCS SP8 AOBS inverted confocal using a 100x oil immersion objec-
tive and 2.5x confocal zoom. The confocal settings were as follows:
pinhole, 1 airy unit, format, 1,024 × 1,024. Images were collected
using the following detection mirror settings: FITC 494-530nm;
Texas red 602-665nm; Cy5 640-690nm. The images were collected
sequentially. Raw images were exported as.lsm files, and adjust-
ments in image contrast and brightness were applied identical for all
images in a given experiment using the freely available software
ImageJ v. 1.52p (Schindelin et al, 2012).
Quantification of the recycling assay
Quantification of recycling was performed as described (Francavilla
et al, 2016). For each time point and each treatment, the presence
(total) and the localization (cell surface versus internalized) of HA-
FGFR2 or endogenous FGFR2 were assessed in at least seven
randomly chosen fields. Approximately 100 cells per condition (both
acid-washed and not) were analysed from three independent
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experiments. The results are expressed as the percentage of receptor-
positive cells (green) over total cells (corresponding to DAPI-stained
nuclei) and referred to the values obtained at time zero. Statistical
analysis was performed across repeats, as indicated in the Fig legends.
Quantification of expression fraction, overlap fraction
and co-localization
Images were pre-processed using an “A trous” wavelet band-pass
filter to reduce the contribution of high-frequency speckled noise to
the co-localization calculations. Pixel intensities were then normal-
ized from the original 8-bit range [0,255] to [0,1]. To ensure that co-
localization was only computed in well-determined regions of inter-
est (ROI), we used the Fiji/ImageJ (Schindelin et al, 2012) built-in
ROI manager to create and record these regions.
To measure differences in expression over time or between
conditions, we computed the fractions of expressed red marker (R),
green marker G. or far-red marker F. pixels over a region of interest







To quantify the overlap fraction between two (R and G) or three
(R, F and G) markers, we first multiplied the (normalized) channel
intensities together, i.e IRG = IR × IG and IRFG = IR × IF × IG to
compute a new image whose intensity increases to 1 where the
markers strongly overlap and decreases or becomes null for non-
overlapping pixels. Our overlap fraction coefficient (OF) becomes
the fraction of strictly positive pixels in the combined image over







Finally, to quantify the actual level of co-localization between
two markers (e.g. R and G), we used the Manders co-localization
coefficients (MCC) M1 and M2 (Manders et al, 1996). M1 measures
the fraction of the R marker in compartments that also contain the G
marker, and M2, the fraction of the G marker in compartments that
also contain the R marker. Lower-bound thresholds for pixel intensi-
ties IR and IG were automatically determined using the Costes








where with TR and TG are the threshold set by the automated
Costes algorithm for the R and G channels, and IR,C and IG,C pixels
are co-localized if their intensity in the reciprocal channel is above
TR or TG set for that channel.
To measure the simultaneous overlap of our three, red, far-red
and green markers (R, F, G), we first used the overlap image
between marker R and marker F as defined above (i.e. e. IF,R =-
IF × IR). We then measured the MCC co-localization parameter of
this combined image against a Green marker using the MCC formu-
lae above, together with the Costes method to determine the TFR
and TG thresholds.
The scripts for the quantification of co-localization were written
in the Python language, and the code for Costes-adjusted MCC was
taken verbatim from the CellProfiler (McQuin et al, 2018) code base.
Student’s t-test was subsequently used to determine the dif-
ference in pixel overlap fraction or Manders (Costes) coefficient
between different experimental conditions in Figs 1 and Figs 5, and
Appendix Fig S4 and S6.
Data availability
The mass spectrometry proteomics data in Thermo Scientific’s
*.raw format have been deposited to the ProteomeXchange Consor-
tium via the PRIDE (Perez-Riverol et al, 2019) partner repository
with the dataset identifier PXD018184. Submission details: Project
Name: Proximal Phosphoproteomics Approaches revealed a FGFR-
EGFR functional cross-talk Project accession: PXD018184. To
download: https://www.ebi.ac.uk/pride/archive/projects/PXD018184.
The scripts for the quantification of overlap fraction and co-
localization are available on Github at the following address:
https://github.com/manbio/smith_ferguson_coloc.
Expanded View for this article is available online.
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